Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

ImmunityBio (IBRX) Receivables - Net (2016 - 2025)

ImmunityBio (IBRX) has disclosed Receivables - Net for 7 consecutive years, with $42.6 million as the latest value for Q4 2025.

  • Quarterly Receivables - Net rose 1703.86% to $42.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $42.6 million through Dec 2025, up 1703.86% year-over-year, with the annual reading at $42.6 million for FY2025, 1703.86% up from the prior year.
  • Receivables - Net for Q4 2025 was $42.6 million at ImmunityBio, up from $32.0 million in the prior quarter.
  • The five-year high for Receivables - Net was $42.6 million in Q4 2025, with the low at $700000.0 in Q1 2024.
  • Average Receivables - Net over 4 years is $11.4 million, with a median of $2.4 million recorded in 2024.
  • The sharpest move saw Receivables - Net fell 20.54% in 2024, then soared 2332.71% in 2025.
  • Over 4 years, Receivables - Net stood at $1.3 million in 2022, then tumbled by 30.77% to $900000.0 in 2023, then skyrocketed by 162.22% to $2.4 million in 2024, then skyrocketed by 1703.86% to $42.6 million in 2025.
  • According to Business Quant data, Receivables - Net over the past three periods came in at $42.6 million, $32.0 million, and $22.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.